Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)
Inflammation is a strong driver of atherosclerotic cardiovascular disease (ASCVD). There is a large unmet need for therapies that prevent or reduce excessive inflammation while avoiding systemic immunosuppression. We showed previously that selective inhibition of pro-inflammatory interleukin-6 (IL-6...
Main Authors: | Dominik M. Schulte, Georg H. Waetzig, Harald Schuett, Marlies Marx, Berenice Schulte, Christoph Garbers, Juliane Lokau, Ann-Kathrin Vlacil, Juliane Schulz, Anna K. Seoudy, Bernhard Schieffer, Philip Rosenstiel, Marcus Seeger, Matthias Laudes, Stefan Rose-John, Ulf Lützen, Karsten Grote, Stefan Schreiber |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.758233/full |
Similar Items
-
A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling
by: Juliane Lokau, et al.
Published: (2021-11-01) -
Sistema de gestão pedagógica (SGP) e avaliação escolar: a influência de uma tecnologia no agir do coordenador pedagógico
by: Claudia Gonçalves da Silva, et al.
Published: (2020-01-01) -
Estimation of the SGP4 Drag Term from Two Osculating Orbit States
by: Byoung-Sun Lee, et al.
Published: (2003-03-01) -
Estimating the potential of desalinate seawater using solar glass pyramid (SGP) in hot arid zones
by: Rania Rushdy Moussa, et al.
Published: (2021-10-01) -
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
by: Juliane Lokau, et al.
Published: (2020-01-01)